Ring Therapeutics has raised an $86.5M Series C funding round to revolutionize programmable medicine.

 

Ring Therapeutics has raised an $86.5M Series C funding round to revolutionize programmable medicine.  Alexandria Venture Investments, Altitude Life Science Ventures, CJ Investment, Invus, Kyowa Kirin Co., and Partners Investment led the round. Ring Therapeutics is focused on advancing gene therapy through the use of anelloviruses. The company claims that its therapies can be used to treat a number of conditions. Since its inception in 2017, the company has raised $235M in funding. Ring aims to use this funding round to expand to new markets and boost production. The company is based in Cambridge, Massachusetts.